Pancreatic Cancer Research

ResearcherVirginia Commonwealth UniversityNo recent work listed

Paul B. Fisher

ORCID-verified (high confidence, 0.95), identity_conf@1As of 7 November 2026

Matched on ORCID iD 0000-0002-0085-4546; OpenAlex author ID A5031490587, A5109883211; NIH RePORTER profile ID 1861210. Sources: OpenAlex.

Their work

Papers
9 (first author 0, last author 6)
Trials
0
Grants
2
Labs led
1
Collaborators
14
Papers, trials and grants by year

2012: 1 grant · 2013: 1 paper · 2014: 2 papers · 2015: 3 papers · 2016: 1 paper, 1 grant · 2017: none · 2018: none · 2019: none · 2020: none · 2021: none · 2022: none · 2023: 2 papers

Papers 9

  1. Chemoresistance in pancreatic ductal adenocarcinoma: Overcoming resistance to therapy. Co-author DOI 10.1016/bs.acr.2023.02.010↗
  2. Cytoplasmic-delivery of polyinosine-polycytidylic acid inhibits pancreatic cancer progression increasing survival by activating Stat1-CCL2-mediated immunity. Last author DOI 10.1136/jitc-2023-007624↗
  3. Therapy of pancreatic cancer via an EphA2 receptor-targeted delivery of gemcitabine. Co-author DOI 10.18632/oncotarget.7931↗
  4. The Quest for an Effective Treatment for an Intractable Cancer: Established and Novel Therapies for Pancreatic Adenocarcinoma. Last author DOI 10.1016/bs.acr.2015.04.009↗
  5. Reversing translational suppression and induction of toxicity in pancreatic cancer cells using a chemoprevention gene therapy approach. Last author DOI 10.1124/mol.114.094375↗
  6. Pancreatic Cancer Combination Therapy Using a BH3 Mimetic and a Synthetic Tetracycline. Last author DOI 10.1158/0008-5472.can-14-3013↗
  7. Pancreatic cancer-specific cell death induced in vivo by cytoplasmic-delivered polyinosine-polycytidylic acid. Co-author DOI 10.1158/0008-5472.can-14-0819↗
  8. Chemoprevention gene therapy (CGT) of pancreatic cancer using perillyl alcohol and a novel chimeric serotype cancer terminator virus. Last author DOI 10.2174/1566524013666131118110827↗
  9. Chemoprevention gene therapy (CGT): novel combinatorial approach for preventing and treating pancreatic cancer. Last author DOI 10.2174/1566524011313070008↗

Grants 2

  1. New transgenic animal model to study pancreatic cancer R21CA191515↗
  2. Pancreatic Cancer Management by Novel Gene Therapy & Dietary Agents R01CA127641↗

Closest collaborators

The 14 strongest of 14 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Luni Emdad · 9 shared papers, 2013–2023 · strength 0.70
  2. Praveen Bhoopathi · 5 shared papers, 2014–2023 · strength 0.52
  3. Bridget A. Quinn · 7 shared papers, 2013–2016 · strength 0.32
  4. Siddik Sarkar · 4 shared papers, 2013–2015 · strength 0.17
  5. Maurizio Pellecchia · 3 shared papers, 2015–2016 · strength 0.15
  6. Rajan Gogna · 1 shared paper, 2023 · strength 0.15
  7. Vignesh Vudatha · 1 shared paper, 2023 · strength 0.15
  8. Esha Madan · 1 shared paper, 2023 · strength 0.15
  9. Jose Gilberto Trevino · 1 shared paper, 2023 · strength 0.15
  10. Azeddine Atfi · 1 shared paper, 2023 · strength 0.15
  11. Paul Dent · 2 shared papers, 2014–2015 · strength 0.09
  12. Susan Morvaridi · 1 shared paper, 2016 · strength 0.05
  13. Stephen Jacob Pandol · 1 shared paper, 2016 · strength 0.05
  14. Steven R. Grossman · 1 shared paper, 2014 · strength 0.04

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.